Session A, Comorbidities and Hepatitis C

A mini symposium on advances in Hepatitis C frames emerging opportunities and challenges as new therapies target cure and prevention but the virus leaves a legacy that threatens future health. The second half of the session updates key co-morbidities such as TB, cancer, metabolic syndrome that are a focus of current clinical research.

Sunday Afternoon (Starts 2:30 pm):

Chairpersons and Discussants:

Robert R. Redfield, MD, Institute of Human Virology

John Bartlett, MD, PhD, Johns Hopkins University

Alexey Mazus, MD, Head of Moscow Center for HIV/AIDS Prevention and Treatment

Franco Buonaguro, MD, National Cancer Institute "Fondazione Pascale"


  • Shyam Kottilil, MD, PhD, Institute of Human Virology
    Introduction to Hepatitis C Minisymposium

  • Kristen Marks, MD, Weill Cornell Medical College
    HCV treatment as prevention

  • Camilla Graham, MD, Harvard Medical School
    Price, Cost-Effectiveness and Affordability of Hepatitis C Drugs: How Did We Get Into This Mess?

  • Kenneth Sherman, MD, University of Cincinnati Comorbidities and Hepatitis C

  • Barry Peters, MD, Kings College London
    The metabolic and cardiovascular complications of HIV

  • John Bartlett, MD, Johns Hopkins University School of Medicine HIV Infection:
    What's New Novel and Exciting

  • Alexey Mazus, MD, Head of Moscow Center for HIV/AIDS Prevention and Treatment
    HIV/HCV coinfection: modern treatment strategies, problems in Eastern Europe

  • Franco Buonaguro, MD, National Cancer Institute “Fondazione Pascale” Viral and cellular biomarkers in HPV-related cancers

  • Joel Palefsky, MD, University of California, San Francisco Pathogenesis of anal cancer

  • Corey Casper MD, MPH, Fred Hutchinson Cancer Research Center
    Translational Research to Advance the Prevention and Treatment of HIV-Associated Malignancies

  • Richard Chaisson, MD, Johns Hopkins Center for Tuberculosis Research and Center for AIDS Research
    Controlling the Impact of HIV-related Tuberculosis

  • Tracy Sparkes, Pharm.D., University of Maryland School of Pharmac
    Impact of Antiretroviral Regimen on Renal Transplant Outcomes in HIV-Infected Recipients

    Opening Reception 6:30 – 8:15 PM


Session B, Status of HIV Cure Research

Fundamental pathogenesis research is advancing insights about how HIV maintains its latent infection that guide potential therapeutic interventions aimed at virus elimination – or at least a functional cure, given new insights about the abundance of HIV viral integration and the genomic sites HIV targets.

Monday Morning (Starts 8:00 am):

Chairpersons and Discussants:

George Shaw, MD, PhD, University of Pennsylvania

Anders Vahlne, MD, PhD, Karolinska Institutet


  • Robert Siliciano, MD, PhD, Johns Hopkins University
    Unique features of effector to memory transition render CD4+ T cells permissive for latent HIV infection

  • Guido Poli, MD, Vita-Salute San Raffaele University
    Towards Achieving a State of Reversible HIV-1 Latency in Primary Monocyte-Derived Macrophages (MDM) by M1 Polarization

  • Keith Jerome, MD, PhD, University of Washington Lab Medicine
    Genome-directed antiviral endonuclease therapy: promise and perils

  • David Margolis, MD, University of North Carolina at Chapel Hill
    HIV Cure Research: a status report

  • John Frater, MD, PhD, University of Oxford
    Post Treatment Control: what predicts long-term HIV remission?

  • Julie Overbaugh, PhD, Fred Hutchinson Cancer Research Center
    Characterizing the basis for the broad and potent HIV-specific neutralizing antibody response of infants

  • Jonathan Karn, PhD, Case Western Reserve University
    Distinct mechanisms of hormonal control of HIV latency in T-cells and microglial cells

  • Stephen H. Hughes, PhD, National Cancer Institute
    Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

  • Deborah Persaud, MD, Johns Hopkins Children's Center
    HIV Latency and Perinatal Infection

  • Fabio Romerio, PhD, Institute of Human Virology
    The HIV-1 antisense transcript AST promotes latency by recruiting PRC2 to the 5'LTR

  • Paolo Lusso, MD, PhD, National Institute of Allergy and Infectious Diseases
    Sulfotyrosine-Mediated V2-V3 Interaction Stabilizes the HIV-1 Envelope Trimer Facilitating Immune Evasion


Session C, Molecular Epidemiology of Viruses and Cancer

This symposium bridges a broad range of scientific disciplines with the underlying theme of integrating population and basic research to advance scientific insight and public health benefit. Included are fundamental presentations on HIV vaccine, viral genomic studies, cancer genomics and risk, public health translation, HPV, HTLV and polio eradication.

Monday Afternoon (Starts 2:00 pm)

Chairpersons and Discussants:

Stanley Weiss, MD, FACP, FACE, Rutgers New Jersey Medical School

Douglas Blayney, MD, Stanford Cancer Center

Alash'le Abimiku, PhD, Institute of Human Virology

Warren Johnson, MD, Weill Cornell Medical College

James Goedert, MD, National Cancer Institute


  • Mark K. Slifka, PhD, Oregon National Primate Research Center at Oregon Health & Science University
    Vaccines and Mechanisms of Host Defense

  • Beatrice Hahn, MD, Perelman School of Medicine, University of Pennsylvania
    Dissecting HIV-1 Transmission: Understanding Transmitted Founder Virus Biology

  • Man Charurat, PhD, Institute of Human Virology
    Genetic Diversity of HIV Reveals the Epidemiological Role of High Risk Groups in Nigeria

  • Esther H. Chang, PhD, Georgetown University
    A Tumor-Targeting Delivery Platform for p53 Therapy: Translation and Clinical Applications

  • Gloria Yuen Fun Ho, PhD, Albert Einstein College of Medicine
    Insulin and IGFBP-3 Associated with Lung Cancer Susceptibility In Current Smokers

  • Myron Essex, DVM, PhD, T.H. Chan School of Public Health, Harvard University
    The Botswana Combination Prevention Project (BCPP): Addressing the UN 90-90-90 Targets for 2020

  • Sten Vermund, MD, PhD, Institute for Global Health, Vanderbilt University Medical Center
    Stigma and Depression Among Newly Diagnosed HIV Infected MSM in China

  • Howard Strickler, MD, Albert Einstein College of Medicine
    Recent Cohort Data Suggest Revising US Cervical Cancer Screening Practices in HIV+ Women

  • Clement Adebamowo, B.M., Ch.B., Sc.D., FWACS, FACS, Institute of Human Virology
    HPV Associated Cervical Cancer in HIV negative African Women

  • Edward L. Murphy, Jr., MD, MPH, University of California, San Francisco
    Human T lymphotropic virus types 1 and 2 (HTLV-1 and -2) and hepatitis C virus (HCV) epidemiology: lessons from studies of blood donors

  • John Vertefeuille, PhD, Centers for Disease Control and Prevention
    Progress toward poliomyelitis eradication - Nigeria, January 2014-July 2015


Session D, HIV Structural Biology, Immunology and Vaccines

Fundamental understanding of the fine structure of the HIV envelop and insights about the host immune response provide a fundamental framework for advancing the HIV vaccine research agenda. Included in this session are two special lectures that unravel the intricacies of the humoral and Fc effector anti-viral response.

Tuesday Morning (Starts 8:20 am)

Chairpersons and Discussants:

Robert C. Gallo, MD, Director, Institute of Human Virology

Georgia Tomaras, PhD, Duke Human Vaccine Institute

José Esparza MD, PhD, Adjunct Professor, Institute of Human Virology

Nina Russell, MD, Bill and Melinda Gates Foundation

Thomas Lehner, CBE, MD, Kings College London


  • Rogier Sanders, PhD, Weill Cornell Medical College HIV-1 neutralizing antibodies induced by native-like envelope trimmers

  • Kwinten Sliepen MSc, University of Amsterdam Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity

  • John Moore, PhD, Weill Cornell Medical College
    Studies on native-like SOSIP.664 trimers and other forms of Env

  • Heather Desaire, PhD, University of Kansas
    Molecular-level analysis of Env: What's on native trimers and how can we reproduce it in a vaccine?

  • Theresa L. Chang PhD , Rutgers University
    Integrin a4b7 expression increases HIV susceptibility in activated cervical CD4+ T cells via an HIV attachment-independent mechanism

  • Douglas Nixon, MD, PhD, George Washington University
    Cellular Immune correlates Analysis of an HIV-1 Pre-exposure Prophylaxis Trial

  • Antje Heit, MD, PhD, Fred Hutchinson Cancer Research Center
    Vaccination establishes CXCR5+PD1+CD4+ peripheral blood germinal center T follicular helper cell relatives in humans

  • Michel Nussenzweig, MD, PhD, The Rockefeller University
    Special Lecture: Human Antibodies to HIV-1

  • Jeffrey Ravetch, MD, PhD, The Rockefeller University
    Special Lecture: Fc Effector functions in the anti-viral response


Session E, Global Virus Threats: Translation of Basic Science to Public Health Practice

The dual Lifetime Award recipients are honored in this special symposium leading up to the Awards Dinner. The Reinhard Kurth Memorial Lecture is presented by Nobel Laureate Harald zur Hausen and Lifetime Achievement Award recipient and explores emerging insights about the role of zoonotic infections in cancer and multiple sclerosis. Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and Lifetime Achievement Award Recipient presents a special lecture providing a global perspective on ending the HIV pandemic. Leading scientists round out this this symposium with scientific presentations that herald advances in vaccine research, emerging viral threats and the changing landscape of global health translation.

Tuesday Afternoon (Starts 1:00 pm)

Chairpersons and Discussants:

Carl Dieffenbach, PhD, Division of AIDS, National Institute of Allergy and Infectious Diseases

Prof. Dr. med. Bernhard Fleckenstein, Universitätsklinikum Erlangen

Susan Buchbinder, MD, University of California, San Francisco

John Idoko, MD, National Agency for the Control of AIDS


  • Robert C. Gallo, MD, Director, Institute of Human Virology
    Introduction to Reinhard Kurth Memorial Lecture

  • Harald zur Hausen, MD, Nobel Laureate, German Cancer Research Center in the Helmholtz Association
    Reinhard Kurth Memorial Lecture: Zoonotic Origin of Some Common Human Cancers and Multiple Sclerosis?

  • Robert C. Gallo, MD, Director, Institute of Human Virology
    Introduction to Lifetime Achievement Awards

  • Anthony Fauci, MD, National Institute of Allergy and Infectious Diseases
    Ending the HIV/AIDS Pandemic: The Convergence of Treatment and Prevention

  • Barton Haynes, MD, Duke Human Vaccine Institute
    The Pathway to HIV Vaccine Development

  • Larry Corey, MD, Fred Hutchinson Cancer Research Center
    Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”?

  • Erica Ollmann Saphire, PhD, The Scripps Research Institute
    Antibodies Against Ebola Virus: Results of the Viral Hemorrhagic Fever Immunotherapeutic Consortium

  • Cliff Lane, MD, National Institute of Allergy and Infectious Diseases
    Establishment of a Clinical Research Program in the Setting of the Ebola Outbreak in West Africa

  • Salim Abdool Karim, PhD, Director, Centre for the AIDS Programme of Research in South Africa (CAPRISA)
    Advancing Global Health: Lessons from the response to the HIV epidemic

6:15 PM Gala Reception with entertainment by Artists With One Voice
7:00 PM Awards Gala Dinner


Session F, Pathogenesis: Viruses, Cancer and Host Factors

Translation of insights gained from pathogenesis research forms the theme of this session. Included are targeted therapies of HIV, insights about the direct role of HIV in lymphoma, fundamental investigations of HPV, cancer microenvironment, HIV antibody potency and HBV strategies for avoiding immune responses.

Wednesday Morning (Starts 8:30 am)

Chairpersons and Discussants:

Anders Vahlne, MD, PhD, Karolinska Institutet

Eduardo Sotomayor, MD, University of South Florida College of Medicine

Kevin Cullen, MD, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine


  • Mario Stevenson, PhD, University of Miami
    Pharmacologic inhibition of the HIV-1 vif:apobec axis

  • Alfredo Garzino Demo, PhD, Institute of Human Virology
    HIV-1 matrix protein p17 promotes lymphangiogenesis by autophagy-mediated unconventional proteins secretion

  • Wuyuan Lu, PhD, Institute of Human Virology
    A conformational switch that turns on the B cell growth-promoting activity of the HIV-1 matrix protein p17

  • Luigi Buonaguro, MD, National Cancer Institute
    "Fond Pascale" Hepatitis virus associated liver cancer: pathogenesis and immunotherapeutic strategies

  • Isaac Witz, MD, PhD, Tel Aviv University
    Site-Specific Metastasis Revisited

  • Anthony DeVico PhD, Institute of Human Virology Transition State Gp120 Structures as HIV Vaccines

  • Genoveffa Franchini, National Cancer Institute, Bethesda Adjuvant dependent RAS activation and mucosal envelope antibody to V2 correlate with reduced risk of SIVmac251 acquisition

  • Thomas Lehner, CBE, MD, Kings College London
    The role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection

  • Krishanu Ray, PhD, University of Maryland School of Medicine
    Antigenicity of the Human Immunodeficiency Virus Envelope on Virions in Solution by Fluorescence Correlation Spectroscopy


Session G, Immunology and Inflammation

Continuing the focus on pathogenesis research this session extends insights into the fundamental mechanisms of humoral antibodies, plasmacytoid dendritic cells in the HIV reservoir, immunoglobulin effector functions and their manipulation, innate and adaptive immune mechanisms, and characteristics of HIV at the virion level. In this session and throughout each session are podium presentations of research abstracts selected based on merit among the over 100 submitted.

Wednesday Afternoon (Starts 12:45 pm)

Chairpersons and Discussants:

Luigi Buonaguro, MD, National Cancer Institute, "Fond Pascale"

William Hall, PhD, University College Dublin

George Pavlakis, MD, PhD, National Cancer Institute

Leonid Margolis, PhD, National Institute of Child Health and Human Development


  • Ellis L. Reinherz, MD, Dana-Farber Cancer Institute
    Special Lecture: The T cell receptor is a mechanosensor

  • Andrés Finzi, PhD, University of Montreal
    Modulating Env conformation: a new approach to eliminate HIV-1-infected cells

  • Richard Koup, MD, Vaccine Research Center, National Institute of Allergy and Infectious Diseases
    Use of bnAbs and bnAb-based bispecific antibodies to target HIV-expressing cells in vivo

  • Margaret Ackerman, PhD, Thayer School of Engineering at Dartmouth College
    Breaking the species barrier: IgG subclasses in man and macaques

  • Galit Alter, PhD, Harvard Medical School, Ragon Institute of MGH, MIT and Harvard
    Defining protective antibody profiles against HIV utilizing systems serology

  • Falk Nimmerjahn, PhD, Lehrstuhl Genetik, Friedrich-Alexander Universität Erlangen-Nürnberg
    The pro- and anti-inflammatory effector functions of IgG

  • Eric Sundberg, PhD, Institute of Human Virology
    Enzymatic manipulation of antibody Fc-mediated effector functions

  • Leonid Margolis, National Institute of Child Health and Development
    Some HIV-1 virions are more equal than others: Mosaics of Envs on individual HIV virions as evaluated with flow virometry

  • Hua Cheng, PhD, Institute of Human Virology
    TBK1/IKKε, the non-canonical IκB kinases, promote survival and proliferation of HTLV-1-transformed T cells by maintaining Stat3 activity

  • Ira Berkower M.D., Ph.D, Lab of Immunoregulation, FDA
    Live attenuated rubella vectors stably express SIV Gag and HIV Env proteins in a highly immunogenic vaccine platform

  • Kenneth Bagley, PhD, Profectus Biosciences
    DNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge

  • Closing Remarks from Dr. Gallo